INTERNATIONAL CHEMICAL INVESTORS S.E.

AKTUELLES

ICIG announces the appointment of Dr. Michael Quirmbach as CEO & President of CordenPharma Group

26. Juli 2019

CordenPharma Group, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is pleased to announce the appointment of Dr. Michael Quirmbach as Chief Executive Officer & President, effective August 1, 2019.

Michael Quirmbach joined CordenPharma Group in October 2014 as Chief Business Officer and has been member of the Executive Leadership Team. Since then he has been instrumental in establishing CordenPharma in the market as a reputable, trustworthy and world class CDMO to the pharmaceutical industry.

Prior to joining CordenPharma, Michael Quirmbach held several management positions in the CDMO and Biotech industry with companies such as Siegfried, Dr. Reddy’s and Solvias. He holds a degree in Chemistry and a PhD from the Max Planck Research Group at the Institute for Organic Catalysis Research in Rostock (DE) as well as a MBA from La Salle University in Philadelphia (USA).

Michael Quirmbach will succeed Dr. Riku Rautsola as CEO & President of CordenPharma Group. Riku Rautsola will transition to the role of a Senior Advisor to the Executive Leadership Team, in support of a smooth transition.

The Executive Leadership Team of CordenPharma Group will consist of Dr. Michael Quirmbach as CEO & President, Dr. Walter Kittl as COO together with Heiko Serwe, CFO, and Dr. Esua Macniell, Chief Compliance Officer.

“We thank Riku Rautsola for taking the responsibility at CordenPharma at a critical time and are pleased with the appointment of Michael Quirmbach as our new CEO & President of CordenPharma Group. Michael Quirmbach has demonstrated strong leadership and was instrumental in CordenPharma’s continued growth trajectory over the last years to become a major CDMO player to the pharmaceutical industry. Our leadership team is now well positioned to accelerate plans for long-term growth. We are also pleased that Riku will continue to support ICIG and CordenPharma Group as a Senior Advisor to the Executive Leadership Team” state Dr. Achim Riemann and Patrick Schnitzer, Managing Directors of ICIG.

About CordenPharma

CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under four Technology Platforms – Peptides, Lipids & Carbohydrates; Injectables; Highly Potent & Oncology; and Small Molecules – CordenPharma experts translate complex processes, ideas and projects at any stage of development into high-value products. For more information visit www.cordenpharma.com.

About International Chemical Investors Group
International Chemical Investors is a privately owned industrial group with sales in excess of EUR 2 billion and more than 5,200 employees worldwide. ICIG is focusing on three main platforms: Pharmaceuticals under the CordenPharma brand, Fine Chemicals under the WeylChem brand and Chlorovinyls under the Vynova brand. Since inception in 2004, ICIG has grown to operate 25 independent chemicals and pharmaceutical businesses in Europe and the United States, all of which have origins in major global chemical or pharmaceutical corporations. For more information about ICIG: www.ic-investors.com.

Contact:

International Chemical Investors Group
Sibel Cumcu
Phone: +49 69 506 999 0
Email: Info@ic-investors.com

ALLE WEITEREN NACHRICHTEN

Vynova joins the „Operation Clean Sweep®“ program

VYNOVA has signed the Operation Clean Sweep® pledge and is committed to the clear goal of zero emissions of plastic pellets, flakes and powder to the environment.  Operation Clean Sweep® (OCS) is a key sustainability program of the global plastics...

ICIG BUSINESS SERVICES

ACCOUNTING

Zuverlässige Abwicklung von buchhalterischen Prozessen, Jahres- und Konzernabschlüssen.

HUMAN RESOURCES & LEGAL

Professionelle Personalplanung und Organisation.

INFORMATION MANAGEMENT

Die Informationstechnik und die Informationssysteme sind die Nervenstränge jedes erfolgreichen Unternehmens.

REPORTING

Das Team Group Accounting & Group Reporting der ICIG Business Services erstellt den IFRS Konzernabschluss der Gruppe und ist für das weltweite Berichtswesen der ICI Group verantwortlich.

WEITERE INFORMATIONEN

SEITEN

› Startseite

› Leistungen

› Unternehmen

› News

› Kontakt

LEISTUNGEN

› Financial & Accounting
› Human Resources & Legal
› Information Management
› Reporting

UNTERNEHMEN

› Team
› Stellenangebote
› ICI Group
› Standorte

KONTAKT / STANDORTE

WUPPERTAL

(HAUPTSITZ)

ICIG Business Services
GmbH & Co. KG

Schlössersgasse 1
D- 42103 Wuppertal

FRANKFURT

(ZWEIGNIEDERLASSUNG)

ICIG Business Services
GmbH & Co. KG
c/o Allessa GmbH
Alt-Fechenheim 34
D- 60386 Frankfurt

AKTUELLES

ICIG BUSINESS SERVICES

Sommerfest & Innenhof!

Unser Sommerfest war ein voller Erfolg! Es gab durchweg positive Rückmeldungen. Alle haben sich wohlgefühlt, untereinander kennengelernt und den Nachmittag mit gutem Essen genossen. Auch die kleinen Gäste haben sich in unserem „Kinderzimmer" beim...

Neue Räumlichkeiten!

Der Umzug in unser neues Gebäude ist nun endlich abgeschlossen. Auf den drei frisch renovierten Etagen, sorgen untere anderem die neuen Büroräume und der neue Innenhof für eine gute Arbeitsatmosphäre. Auf jeder Etage wird mit Hilfe der neuen...

IC INVESTORS